These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. Gao M, Wang H, Zhu L. Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337 [Abstract] [Full Text] [Related]
23. A new pharmaceutical concept for the treatment of oropharyngeal and oesophageal candidosis with fluconazole. Wildfeuer A, Laufen H, Yeates RA, Zimmermann T. Mycoses; 1996; 39(9-10):357-60. PubMed ID: 9009658 [Abstract] [Full Text] [Related]
32. Itraconazole and fluconazole in oropharyngeal candidiasis. van der Bijl P, Arendorf TM. Ann Dent; 1993; 52(2):12-6. PubMed ID: 8267372 [Abstract] [Full Text] [Related]
33. EUCAST technical note on fluconazole. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)Department of Haematology, UMC St Radboud, Radboud University, Nijmegen, The Netherlands.. Clin Microbiol Infect; 2008 Feb; 14(2):193-5. PubMed ID: 18070130 [No Abstract] [Full Text] [Related]
36. Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. Penk A, Pittrow L. Mycoses; 1999 Feb; 42 Suppl 2():97-100. PubMed ID: 10865913 [Abstract] [Full Text] [Related]
38. Oral fluconazole for vaginal candidiasis. Desai PC, Johnson BA. Am Fam Physician; 1996 Sep 15; 54(4):1337-40, 1345-6. PubMed ID: 8816577 [Abstract] [Full Text] [Related]
39. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. Vazquez JA. HIV Clin Trials; 2000 Sep 15; 1(1):47-59. PubMed ID: 11590489 [Abstract] [Full Text] [Related]